. 2022 Aug 26;41(12):3807–3816. doi: 10.1007/s10067-022-06350-5

Table 3.

Treatment approach of moderate and severe MIS-C patients

	All patients (n = 123)	Mild/moderate MIS-C (n = 75)	Severe MIS-C (n = 48)	p value
Use of corticosteroids^d n (%)				< 0.001^a
Prednisolone (2 mg/kg)^a	36 (29.3)	36 (64.3)	0 (0)
Methylprednisolone (30 mg/kg)^a	68 (55.3)	20 (26.7)	48 (100)
Indication for using steroid^e n (%)				< 0.001^a
Low LVEF/hypotension	68 (68.7)	23 (45.1)	45 (93.7)
Resistant fever	24 (24.2)	21 (41.2)	3 (6.3)
Gastrointestinal symptoms	5 (5.1)	5 (9.8)	0 (0)
Persistent elevation in acute phase reactants	2 (2)	2 (3.9)	0 (0)
Duration of steroid use^† (day)	30 (24–36)^f	27 (22–31.5)	35 (28.3–44.8)	< 0.001^b
Anakinra n (%)	42 (34.4)	6 (8.1)	36 (75)	< 0.001^a
Anakinra dosage (mg/kg/day)^†	6,6 (5.5–7.7)^g	5,5 (4.8–6.7)	6.6 (6–7.9)	0.13^b
Duration of Anakinra use^† (day)	11 (10–13)^g	10 (7.3–11)	12 (10–14)	0.060^b
Plasmapheresis n (%)	24 (19.5)	1 (1.3)	23 (47.9)	< 0.001^a

^†Median (ınterquartile range)

^aChi-square

^bMann-Whitney U

^d104 patients received corticosteroid therapy

^e5 patients not available for assessment

^f7 patients not available for assessment

^g42 patients recieved anakinra

LVEF, left ventricular ejection fraction